Droplet microfluidics is revolutionizing single-cell analysis and selection in biopharma. In his latest article for Lab + Life Scientist, Sphere Bio’s Chief Technology Officer, Richard Hammond, explores how this established technology is driving advances in cell characterization and selection, offering efficiency, precision, and scalability.

✅ Enhanced Cell Selection – Droplet microfluidics enables high-throughput screening, rapidly assessing large cell populations and isolating high-value clones.
✅ Optimal Cell Environment – The method maintains cell viability while shielding them from shear forces and supporting gas exchange.
✅ Automation & Cost Efficiency – With microfluidic channels streamlining workflows, the approach reduces reagent use and operational complexity.
✅ Advanced Assay Techniques – The latest innovations enhance specificity and multiplexing, identifying critical phenotypes with precision.

Droplet-based systems continue to evolve, offering deeper insights into cellular behavior and streamlining biopharma workflows. As technology advances, the ability to move from millions of cells to a select few with desired characteristics is becoming more achievable than ever.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or explore our cutting-edge solutions for high-throughput screening and single-cell analysis.

This is part of our Editorial Coverage series, highlighting Sphere Bio’s contributions to leading scientific and industry publications. Stay updated on how our technology is shaping the future of biopharmaceutical discovery.